Evaluation of the ALIBIRD mHealth Platform for Patient Monitoring in Lung Cancer: Prospective Interventional Study (Preprint)

Résumé fourni par la source

BACKGROUND Mobile Health (mHealth) represents a promising instrument for optimizing symptom management and important lifestyle strategies that enhance self-care and the quality of healthcare for cancer patients. The ALIBIRD mHealth is a digital health solution specifically designed for the telemonitoring of oncology patients, fostering patient empowerment and supporting clinical decision-making. OBJECTIVE The primary objective of this study was to evaluate the patient experience with the ALIBIRD platform. Additionally, the study aimed to assess clinical outcomes, particularly in symptom management, nutritional status, and lifestyle, using patient-reported outcome measures. METHODS The evaluation of the mHealth platform was conducted over a 30-week period involving patients with advanced lung cancer who were undergoing active treatment. Through a mobile application, patients reported their symptoms and lifestyle data while receiving personalized recommendations, which included nutrigenetic and microbiota reports. Clinicians monitored patient data remotely using a web-based tool and executed various clinical interventions, including phone calls, therapeutic adjustments, referrals, and appointment rescheduling. RESULTS Out of 20 patients recruited for the study, 14 completed the intervention. The System Usability Scale yielded a score of 90, indicating high levels of patient satisfaction. The ALIBIRD platform collected and processed 3,589 patient-reported outcomes related to physical activity, 3,468 related to sleep, 679 on-demand symptom entries, and 1,524 completed questionnaires. Clinically, 143 alerts were resolved within an average of 2.05 days, resulting in two referrals to emergency rooms and two early detections of disease progressions. Furthermore, over 2,100 personalized recommendations contributed to a 21% increase in adherence to the Mediterranean diet and a 14.28% increase in moderate physical activity. CONCLUSIONS The evaluation of the ALIBIRD implementation yielded promising results in that it facilitated the adoption of healthier life-style habits while enhancing health self-management among oncology patients. The ALIBIRD mHealth platform emerges as an effective digital health tool that enables closer monitoring of patients and thereby more informed clinical decision-making. CLINICALTRIAL ClinicalTrials.gov NCT05770869

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.